FY24: Logistics & IT, digital innovation shine bright

12/03/25 -"Galenica reported a strong FY 2024 performance, with sales increasing by 4.7%, driven by growth across all segments except ‘at-home’ pharmacies. Adjusted EBIT increased by 10.3%, ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

12/03/25

Download

You may also be interested by these reports :

31/07/26

Avolta

Results in line despite the Middle East drag, an FX headwind and the JFK and Pudong ramp-up compressing margins. The regional mix diverged: North ...

29/07/26

Avolta

We are updating Avolta’s model ahead of H1 2026. Overall, we have slightly lowered our TP to reflect the geopolitical headwinds whose ‘temporary’ ...

29/07/26

Redcare Pharmacy

2Q26: Sales +20%, adj. EBITDA +65.7% yoy – FY26E guidance confirmed

28/07/26

Rexel

Rexel reported H1’26 results ahead of both consensus and AV estimates, driven by strong North American data centre demand, improving European ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue